CoChat

Management challenges and therapeutic advances in congenital adrenal hyperplasia

Open access
Mallappa, Ashwini, Merke, Deborah P. · 2022 · Nature Reviews Endocrinology

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index; 30 of the 174 sources its claims cite were checked for support.

Abstract

Treatment for congenital adrenal hyperplasia (CAH) was introduced in the 1950s following the discovery of the structure and function of adrenocortical hormones. Although major advances in molecular biology have delineated steroidogenic mechanisms and the genetics of CAH, management and treatment of this condition continue to present challenges. Management is complicated by a combination of comorbidities that arise from disease-related hormonal derangements and treatment-related adverse effects. The clinical outcomes of CAH can include life-threatening adrenal crises, altered growth and early puberty, and adverse effects on metabolic, cardiovascular, bone and reproductive health. Standard-of-care glucocorticoid formulations fall short of replicating the circadian rhythm of cortisol and controlling efficient adrenocorticotrophic hormone-driven adrenal androgen production. Adrenal-derived 11-oxygenated androgens have emerged as potential new biomarkers for CAH, as traditional biomarkers are subject to variability and are not adrenal-specific, contributing to management challenges. Multiple alternative treatment approaches are being developed with the aim of tailoring therapy for improved patient outcomes. This Review focuses on challenges and advances in the management and treatment of CAH due to 21-hydroxylase deficiency, the most common type of CAH. Furthermore, we examine new therapeutic developments, including treatments designed to replace cortisol in a physiological manner and adjunct agents intended to control excess androgens and thereby enable reductions in glucocorticoid doses. This Review focuses on challenges and advances in the management and treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. New therapeutic developments are discussed, including novel glucocorticoid therapies, adjunct agents aimed at controlling excess androgens, and cell-based and gene-based therapies. Challenges in the management of congenital adrenal hyperplasia (CAH) arise from multiple hormonal imbalances, the intrinsic tendency of the CAH-affected adrenal gland to overproduce androgens and limited treatment options, which often necessitate glucocorticoid excess. The relationship between glucocorticoid and mineralocorticoid actions should be considered in the management of replacement therapies in CAH. Patients are at risk of life-threatening adrenal crises with hypoglycaemia, most often triggered by infectious illnesses and exacerbated by adrenaline deficiency. Traditional biomarkers vary with glucocorticoid dose or time of day and are not adrenal-specific, reflecting the need for new biomarkers; for example, the biologically active 11-oxygenated androgens, which are elevated in CAH. Circadian glucocorticoid replacement and adjunct non-glucocorticoid therapies promise to enable glucocorticoid dose reduction; furthermore, the development of personalized gene and cellular therapies is under way. Challenges in the management of congenital adrenal hyperplasia (CAH) arise from multiple hormonal imbalances, the intrinsic tendency of the CAH-affected adrenal gland to overproduce androgens and limited treatment options, which often necessitate glucocorticoid excess. The relationship between glucocorticoid and mineralocorticoid actions should be considered in the management of replacement therapies in CAH. Patients are at risk of life-threatening adrenal crises with hypoglycaemia, most often triggered by infectious illnesses and exacerbated by adrenaline deficiency. Traditional biomarkers vary with glucocorticoid dose or time of day and are not adrenal-specific, reflecting the need for new biomarkers; for example, the biologically active 11-oxygenated androgens, which are elevated in CAH. Circadian glucocorticoid replacement and adjunct non-glucocorticoid therapies promise to enable glucocorticoid dose reduction; furthermore, the development of personalized gene and cellular therapies is under way.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41574-022-00655-w

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

24 Valid · 0 Not valid · 106 Not checked · 24 Own results and interpretations

83 more claims · 9 with their cited sources checked

Create a free account to see all 154 claims and to verify the 144 references still open.

See all claims — free account
  • It may state two separate claims as one. 63
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 156 references

Cited by

See all 113

Metadata

Authors
Mallappa, A., & Merke, D. P.
Affiliations
National Institutes of Health (US)
Corresponding author
Merke, Deborah P.
Venue
Nature Reviews Endocrinology
Published
2022-04-11
Volume
18
Issue
6
Pages
337-352
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W4223486597
Cited by
113
References
157
Citations by year
2026: 19 · 2025: 23 · 2024: 35 · 2023: 27 · 2022: 9
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Endocrinology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
congenital adrenal hyperplasia, 21-hydroxylase deficiency, glucocorticoid therapy, adrenal crisis, hyperandrogenism, 11-oxygenated androgens, biomarkers, diurnal cortisol rhythm, adrenal androgen production, steroid-sparing therapy, cell therapy, gene therapy, steroidogenesis, comorbidities
MeSH terms
Adrenal Hyperplasia, Congenital, Androgens, Glucocorticoids, Humans, Hydrocortisone, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management challenges and therapeutic advances in congenital adrenal hyperplasia. https://app.cochat.ai/papers/10.1038/s41574-022-00655-w
The paper
Mallappa, A., & Merke, D. P. (2022). Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00655-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.